Приказ основних података о документу
Selective Anti-Cancer Drugs against Multi-drug Resistance
dc.contributor | Ur-Rahman, Atta | |
dc.contributor | Choudhary, M. Iqbal | |
dc.creator | Stanković, Tijana | |
dc.creator | Podolski-Renić, Ana | |
dc.creator | Dinić, Jelena | |
dc.creator | Pešić, Milica | |
dc.date.accessioned | 2020-09-16T09:02:45Z | |
dc.date.available | 2900-01-01 | |
dc.date.issued | 2018 | |
dc.identifier.isbn | 978-1-68108-702-3 | |
dc.identifier.issn | 2451-8395 | |
dc.identifier.uri | https://www.eurekaselect.com/168130/chapter/ | |
dc.identifier.uri | https://radar.ibiss.bg.ac.rs/123456789/3874 | |
dc.description.abstract | Collateral sensitivity (CS) is a phenomenon in which development of multidrug resistance (MDR) in cancer cells confers higher sensitivity to other drugs compared to parental cells. This means that along with advantages, MDR cancer cells may adopt certain weaknesses. Therefore, MDR phenotype became a target for the development of new drugs, termed MDR-selective compounds. These compounds may exploit the overexpression of ATP Binding Cassette (ABC) transporters, directly acting on transporters’ ATPase function or indirectly acting on mechanisms independent of transporters activity. Herein, we review the current findings regarding the specific mechanisms of MDR selective drugs, their potential use in combination with other drugs or chemotherapeutics and perspectives in finding new anti-cancer options for MDR treatment. | en |
dc.language.iso | en | sr |
dc.publisher | Sharjah: Bentham Science Publishers | sr |
dc.relation | info:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41031/RS// | sr |
dc.rights | restrictedAccess | sr |
dc.source | Frontiers in Anti-Cancer Drug Discovery | sr |
dc.subject | Autophagy | sr |
dc.subject | Anti-Cancer Agents | sr |
dc.subject | ATP-Binding Cassette (ABC) Transporters | sr |
dc.subject | ABC Transporters’ Inhibitors | sr |
dc.subject | Antioxidant Capacity | sr |
dc.subject | Collateral Sensitivity | sr |
dc.subject | Energetic Sensitivity | sr |
dc.subject | Glutathione Depletion | sr |
dc.subject | Microtubule Composition | sr |
dc.subject | Multi-drug Resistance | sr |
dc.subject | Plasma Membrane Symmetry | sr |
dc.title | Selective Anti-Cancer Drugs against Multi-drug Resistance | sr |
dc.type | bookPart | sr |
dc.rights.license | ARR | sr |
dcterms.abstract | Подолски-Ренић, Aна; Станковић, Тијана; Пешић, Милица; Динић, Јелена; Селецтиве Aнти-Цанцер Другс агаинст Мулти-друг Ресистанце; Селецтиве Aнти-Цанцер Другс агаинст Мулти-друг Ресистанце; | |
dc.rights.holder | © 2018 Bentham Science Publishers | sr |
dc.citation.volume | 9 | |
dc.description.other | Ur-Rahman A, Choudhary MI, editors. Frontiers in Anti-Cancer Drug Discovery. Sharjah: Bentham Science Publishers; 2018. p. 114-92. | |
dc.identifier.doi | 10.2174/9781681087016118090006 | |
dc.citation.spage | 114 | |
dc.citation.epage | 192 | |
dc.type.version | publishedVersion | sr |
dc.citation.rank | M14 |